Clene Inc
CLNN
Company Profile
Business description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Contact
6550 South Millrock Drive
Suite G50
Salt Lake CityUT84121
USAT: +1 801 676-9695
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2025
Employees
76
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,216.83 | 8.80 | -0.11% |
| DAX 40 | 24,274.11 | 34.22 | 0.14% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,639.00 | 6.62 | -0.07% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |